Viking Therapeutics股票表现 - Viking Therapeutics股票周二早盘上涨12.5%至10.83美元[1] - 周一Truist Securities分析师下调目标价但仍看好VK2735三期临床试验消息的积极影响[2] - Cantor Fitzgerald分析师Steven Seedhouse给予买入评级并预测股价将从29美元飙升至104美元[2] VK2735药物分析 - VK2735是GLP-1/GIP双重激动剂即将进入三期临床试验用于治疗普通肥胖症[3] - 公司正在开发VK2735口服剂型预计2025年第二季度公布二期数据[3] - 分析师认为即使仅推出注射剂型也足以使股价增长三倍以上[3] 竞争格局评估 - VK2735配方被认为优于礼来公司的tirzepatide具有更强效性[4] - 分析师预测该药物将超越礼来的Zepbound和Mounjaro[4] - 若预测准确VK2735有望成为超级重磅药物[4] 研发进展 - 注射剂型VK2735处于三期临床开发阶段[3] - 口服剂型研发进展顺利二期数据即将公布[3] - 临床试验结果将决定药物最终商业价值[4]

文章核心观点 2025年是判断Viking Therapeutics股票是否成功的一年 公司虽面临肥胖领域竞争但开展新药3期临床试验有望带来积极成果 不过目前仍是投机性股票 [1][2][5] 公司情况 - Truist Securities分析师Joon Lee将Viking Therapeutics无盈利生物科技股目标价从每股95美元降至75美元 警告公司面临肥胖领域竞争加剧 [1] - 2025年公司将开启新GLP - 1肥胖药物VK2735的3期临床试验 若试验结果良好 公司有望成为减肥领域第三大投资对象 [1][2] - S&P Global Market Intelligence调查的分析师预测 公司今年收入不到200万美元 预计到2027年增至3800万美元 到2029年达7.29亿美元且首次实现盈利 [4] 投资建议 - 公司目前无营收和利润 若有药物上市将是重大成功 但从现在到盈利还有很多事要顺利推进 3期试验若失败情况可能迅速恶化 [3][5] - 公司股票目前是投机性股票 若要购买应少量并保持投资多元化 [5]

VIKING THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other juris ...

Viking Therapeutics (VKTX) reported a first-quarter 2025 loss of 41 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents. The company had incurred a loss of 26 cents in the year-ago quarter.Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it has yet to generate revenues. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)More on VKTX’s Q1 EarningsResearch and development expenses surged 72% year over year to $41.4 mil ...

Exhibit 99.1 Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, April 23, 2025 -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on its clinical pipeline and other corpo ...

Conference call scheduled for 4:30 p.m. ET today Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25 Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25 Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735 Strong Quarter-End Cash Position of $852 MillionSAN DIEGO, April 23, 2025 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therap ...

核心观点 - 公司即将在23日发布一季度财报 投资者电话会议预计将聚焦于关键研发管线进展[1] - 重点关注三种临床候选药物：VK2735(肥胖症)、VK2809(非酒精性脂肪性肝炎)、VK0214(X连锁肾上腺脑白质营养不良)[1] - 肥胖症治疗领域被视为消费健康领域具有强大增长潜力的趋势 其中VK2735最受关注[2] 研发管线 - VK2735定位肥胖症治疗领域 该领域标杆药物为已获FDA批准的tirzepatide(商品名Mounjaro®和Zepbound®)[2] - VK2809针对非酒精性脂肪性肝炎(NASH)治疗[1] - VK0214针对X连锁肾上腺脑白质营养不良(X-ALD)治疗[1] 技术面分析 - 股价在4月7日当周形成经典反转底部形态[3] - 相对强度指标显示其表现优于基准指数[3] - 动量指标虽未突破50日均线 但正在接近该关键位[3] - 周线图显示处于派发阶段而非熊市阶段 200周均线(绿色)构成重要支撑位[4] - 当前股价回落至2023年底水平(此前曾飙升至100美元峰值)[5] - 若周线收盘突破24.50美元将形成积极信号 潜在回报可达风险的4-5倍[5]

文章核心观点 - 受特朗普宏观经济政策影响今年股市表现不佳 投资者可寻找下跌的优质股票进行投资 推荐Viking Therapeutics和PayPal两只今年跌幅至少25%的股票 [1] Viking Therapeutics - 临床阶段的生物技术公司 专注开发代谢和内分泌疾病药物 因领先候选药物VK2735出色的2期数据去年声名鹊起 [2] - VK2735数据强劲 抗肥胖药物市场增长迅速且竞争激烈 很少有药物中期结果能与之匹配 [3] - VK2809治疗代谢功能障碍相关脂肪性肝炎的2期数据良好 VK0214治疗X连锁肾上腺脑白质营养不良的1期研究近期完成 [4] - 公司正在开发模仿两种激素作用的下一代减肥药 双激动剂在该领域越来越受欢迎 [5] - 公司不断寻找新机会 虽临床前候选药物可能不成功 但临床和监管进展未来几年可能带来大幅收益 适合能接受一定波动的投资者少量建仓 [6] PayPal - 今年股价下跌 因第四季度业绩未达投资者预期 Braintree支付处理平台增长未达华尔街预期 市场动荡加剧了抛售 [7] - Braintree第四季度表现不佳是公司主动放弃无利可图业务量 虽短期销售和销售增长下降 但未来该业务利润和利润率将提高 [8] - 公司近年来业务有重要变化 广告业务是有吸引力的机会 公司是受信任的金融服务品牌 2024年底有4.34亿活跃账户 同比增长2% 众多商家接受其支付 广告平台连接零售交易双方或成重要收入来源 [9] - 公司平台有网络效应 生态系统内商家越多对消费者越有吸引力 反之亦然 这使其能长期保持金融科技领域领先地位 鉴于行业长期前景 公司有望取得良好业绩和股市表现 今年股价下跌26% 现在值得买入 [10][11]

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

Viking Therapeutics TodayVKTXViking Therapeutics$22.98 -0.13 (-0.55%) 52-Week Range$18.92▼$81.86Price Target$89.75Add to WatchlistViking Therapeutics Inc. NASDAQ: VKTX has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its closing price on January 2, 2024. But it’s been a steady move lower. As of the market close on April 15, 2025, the stock is within 10% of that January 2024 close. This week alone has been wild. Viking stock shot up approximately 12% ...